Growth Metrics

Apellis Pharmaceuticals (APLS) Current Leases (2020 - 2025)

Historic Current Leases for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $7.0 million.

  • Apellis Pharmaceuticals' Current Leases rose 338.63% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year increase of 338.63%. This contributed to the annual value of $6.8 million for FY2024, which is 484.4% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Current Leases of $7.0 million as of Q3 2025, which was up 338.63% from $7.4 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Current Leases ranged from a high of $7.4 million in Q2 2025 and a low of $3.9 million during Q1 2021
  • Over the past 5 years, Apellis Pharmaceuticals' median Current Leases value was $5.8 million (recorded in 2023), while the average stood at $5.7 million.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Current Leases skyrocketed by 5146.4% in 2021 and then skyrocketed by 338.63% in 2025.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Current Leases stood at $4.1 million in 2021, then surged by 36.7% to $5.6 million in 2022, then grew by 14.51% to $6.4 million in 2023, then increased by 4.84% to $6.8 million in 2024, then grew by 3.98% to $7.0 million in 2025.
  • Its Current Leases stands at $7.0 million for Q3 2025, versus $7.4 million for Q2 2025 and $6.9 million for Q1 2025.